Home/Investors/MPM Capital

MPM Capital

Biotech Investor · 8 portfolio companies

Portfolio

8

Combined Value

$2.9B

Focus Areas

12

Top Stage

preclinical

Investment Focus

Neuromuscular Diseases Genetic Disorders Cardiovascular Regenerative Medicine Rare Disease Neuroscience Neurodegenerative Diseases Oncology Immunology Infectious Disease Genetic Diseases Neurology

Portfolio Companies

Company	Stage	Valuation	Focus
Dyne Therapeutics	Phase 1/2	$2.9B	Neuromuscular Diseases, Genetic Disorders
Vita Therapeutics	preclinical	—	Cardiovascular, Regenerative Medicine
Vima Therapeutics	preclinical	—	Neuroscience, Neurodegenerative Diseases
QL Biopharm	preclinical	—	Oncology
NextPoint Therapeutics	preclinical	—	Oncology, Immunology
Orna Therapeutics	preclinical	—	Oncology, Infectious Disease
NeuroHeal	phase-2	—	Neuroscience, Regenerative Medicine
ReNAgade Therapeutics	preclinical	—	Genetic Diseases, Neurology

Frequent Co-Investors

Atlas Venture2 shared OrbiMed1 shared Dementia Discovery Fund1 shared ARCH Venture Partners1 shared Novo Holdings1 shared Cambrian Biopharma1 shared Revere Partners1 shared Vida Ventures1 shared